J Lewin, L Sayers, D Kee, I Walpole, A Sanelli, L Te Marvelde, A Herschtal, J Spillane, D Gyorki, D Speakman, V Estall, S Donahoe, M Pohl, K Pope, M Chua, S Sandhu, G A McArthur, C J McCormack, M Henderson, R J Hicks, M Shackleton
Background: As early detection of recurrent melanoma maximizes treatment options, patients usually undergo post-operative imaging surveillance, increasingly with FDG-PET/CT (PET). To assess this, we evaluated stage 3 melanoma patients who underwent prospectively applied and sub-stage-specific schedules of PET surveillance. Patients and Methods: From 2009, patients with stage 3 melanoma routinely underwent PET +/- MRI brain scans via defined schedules based on sub-stage-specific relapse probabilities...
April 12, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology